RecruitingPhase 1Phase 2NCT05170958
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Enrollment
396 participants
Start Date
Jan 6, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria6
- Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form;
- 18-75 years old (including boundary value), no gender limit in the I/IIa trial phase；18-80 years old (including boundary value), no gender limit in the IIb trial phase；
- Subject has adequate organ and bone marrow function，Conforming to laboratory test results:
- The expected survival time is at least 12 weeks
- ECOG score is 0-1
- Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.
Exclusion Criteria5
- Receiving other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time;
- Brain parenchymal metastases or meningeal metastases with clinical symptoms, which are not suitable for inclusion in the group by the investigator's judgment;
- medical history of immunodeficiency including positive HIV antibody test;
- Women who are pregnant or breastfeeding;
- The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLBL-024 for Injection
LBL-024 was given every three weeks for treatment
Locations(49)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05170958
Related Trials
First in Human Study of T3P-Y058-739 (T3P)
NCT0512059615 locations
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT0663578519 locations
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT063523598 locations
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT063623695 locations
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
NCT064876247 locations